Collaboration with US Pharma

12 January, 2017

IMB Researchers in collaboration with Noliva Therapeutics (Newton, Massachusetts) report chemical silencing of a protein-protein interaction using a rationally designing ligand that binds selectively and irreversibly to the cancer target, the protein Bcl2A1. “Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein–Protein Interaction Site.” Aline Dantas de Araujo, Junxian Lim, Andrew C. Good, Renato T. Skerlj and David P. Fairlie. ACS Med Chem Lett 2017, 8, 22-26 [Featured Letter]